PEAK6 Investments LLC Takes $1.14 Million Position in Envista Holdings Co. (NYSE:NVST)

PEAK6 Investments LLC bought a new position in Envista Holdings Co. (NYSE:NVST) in the third quarter, Holdings Channel.com reports. The firm bought 57,879 shares of the company’s stock, valued at approximately $1,144,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVST. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Envista during the third quarter worth $31,000. GAMMA Investing LLC raised its stake in shares of Envista by 69.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after buying an additional 726 shares during the last quarter. Huntington National Bank raised its stake in shares of Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after buying an additional 949 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after buying an additional 804 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Envista by 50.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after acquiring an additional 728 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have commented on NVST. Wells Fargo & Company started coverage on Envista in a research report on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 price objective on the stock. Leerink Partners upgraded shares of Envista from an “underperform” rating to a “market perform” rating and raised their price target for the company from $16.00 to $23.00 in a research report on Thursday, October 31st. Stifel Nicolaus upped their price objective on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Evercore ISI increased their target price on shares of Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a research note on Monday, September 23rd. Finally, Bank of America cut their price target on Envista from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Envista has a consensus rating of “Hold” and a consensus price target of $20.71.

Envista Stock Performance

NYSE NVST opened at $22.31 on Tuesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The stock’s 50 day simple moving average is $19.79 and its 200-day simple moving average is $18.28. The company has a market cap of $3.84 billion, a PE ratio of -2.87, a price-to-earnings-growth ratio of 3.10 and a beta of 1.30. Envista Holdings Co. has a 1-year low of $15.15 and a 1-year high of $25.64.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The company had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. During the same quarter last year, the firm posted $0.43 EPS. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. As a group, equities research analysts anticipate that Envista Holdings Co. will post 0.72 EPS for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.